Use of bevacizumab with capecitabine was evaluated in the multicentre, placebo-controlled, phase 3 RIBBON-1 study in patients with HER2-negative metastatic or locally recurrent breast cancer. Patients (n=1237) were randomised to receive chemotherapy plus bevacizumab or chemotherapy plus placebo every 3 weeks. Chemotherapy options included capecitabine, a taxane and anthracycline-based agents.
For statistical analysis, patients were divided into 2 cohorts defined by chemotherapy received. The primary endpoint, median progression-free survival, was longer for capecitabine plus bevacizumab than for capecitabine plus placebo: 8.6 months vs 5.7 months, with a hazard ratio of 0.69 (95% CI 0.56-0.84; p<0.001).